Literature DB >> 27117206

A false positive newborn screening result due to a complex allele carrying two frequent CF-causing variants.

Anne Bergougnoux1, Amandine Boureau-Wirth2, Cécile Rouzier2, Jean-Pierre Altieri3, Fanny Verneau3, Lise Larrieu3, Michel Koenig4, Mireille Claustres4, Caroline Raynal4.   

Abstract

The detection of two frequent CFTR disease-causing variations in the context of a newborn screening program (NBS) usually leads to the diagnosis of cystic fibrosis (CF) and a relevant genetic counseling in the family. In the present study, CF-causing variants p.Phe508del (F508del) and c.3140-26A>G (3272-26A>G) were identified on a neonate with positive ImmunoReactive Trypsinogen test by the Elucigene™ CF30 kit. The CF diagnosis initially suggested, despite three inconclusive Sweat Chloride Tests (SCT), was finally ruled out after the familial segregation study combined with a negative SCT. Haplotype studies, based on the comparison of 80 p.Phe508del haplotypes, suggested a probable de novo occurrence of c.3140-26A>G on the p.Phe508del ancestral allele in this family. This false positive case emphasizes the importance of SCT in the NBS strategy. Moreover, it raises the need for familial segregation studies in CF and in overall molecular diagnosis strategy of autosomal recessive diseases.
Copyright © 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CFTR gene; Complex allele; Cystic fibrosis; False positive; Newborn screening

Mesh:

Substances:

Year:  2016        PMID: 27117206     DOI: 10.1016/j.jcf.2016.04.003

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  7 in total

1.  Optimization of the French cystic fibrosis newborn screening programme by a centralized tracking process.

Authors:  Anne Munck; Dominique Delmas; Marie-Pierre Audrézet; Lydie Lemonnier; David Cheillan; Michel Roussey
Journal:  J Med Screen       Date:  2017-04-28       Impact factor: 2.136

2.  What can the CF registry tell us about rare CFTR-mutations? A Belgian study.

Authors:  E De Wachter; M Thomas; S S Wanyama; S Seneca; A Malfroot
Journal:  Orphanet J Rare Dis       Date:  2017-08-22       Impact factor: 4.123

3.  Novel, rare and common pathogenic variants in the CFTR gene screened by high-throughput sequencing technology and predicted by in silico tools.

Authors:  Stéphanie Villa-Nova Pereira; José Dirceu Ribeiro; Antônio Fernando Ribeiro; Carmen Sílvia Bertuzzo; Fernando Augusto Lima Marson
Journal:  Sci Rep       Date:  2019-04-17       Impact factor: 4.379

4.  Prenatal Diagnosis of Cystic Fibrosis and Hemophilia: Incidental Findings and Weak Points.

Authors:  Marika Comegna; Giuseppe Maria Maruotti; Laura Sarno; Gustavo Cernera; Monica Gelzo; Maurizio Guida; Fulvio Zullo; Federica Zarrilli; Giuseppe Castaldo
Journal:  Diagnostics (Basel)       Date:  2019-12-21

Review 5.  The Role of Extended CFTR Gene Sequencing in Newborn Screening for Cystic Fibrosis.

Authors:  Anne Bergougnoux; Maureen Lopez; Emmanuelle Girodon
Journal:  Int J Neonatal Screen       Date:  2020-03-21

Review 6.  Processing Newborn Bloodspot Screening Results for CF.

Authors:  Jürg Barben; Jane Chudleigh
Journal:  Int J Neonatal Screen       Date:  2020-03-25

Review 7.  Molecular Diagnosis and Genetic Counseling of Cystic Fibrosis and Related Disorders: New Challenges.

Authors:  Thierry Bienvenu; Maureen Lopez; Emmanuelle Girodon
Journal:  Genes (Basel)       Date:  2020-06-04       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.